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Groups HL Progression Overall Mortality
N HR (95% CI) p-value HR (95% CI) p-value
BEAM 313 1.00 - 1.00 -
CBVlow 279 1.12 (0.85-1.47) 0.43 1.53 (1.16-2.02) 0.003
CBVhigh 219 0.95 (0.71-1.28) 0.74 1.54 (1.15-2.05) 0.003
BuCy 162 1.52 (1.13-2.05) <0.001 1.77 (1.30-2.43) <0.001
TBI 23 1.94 (1.09-3.45) 0.024 3.39 (2.03-5.64) <0.001
Table 1
Patient Characteristics and Outcome
13q (n¼42) 13q+ (n¼34)
Age (years) 65 (88-44) 13q+ (n¼34)
Gender
Male 19 (45%) 15
Female 23 (55%) 19 (55%)
Race
White 13 (30%) 11 (32%)
African American 27 (65%) 20 (60%)
Other 2 3
International Staging System at diagnosis
I 5 (15%)
II 3 (7%) 4 (12%)
III 26 (62%) 30 (88%)
Plamacytoma 9 (21%) 12 (35%)
Bortezomib based Induction
Regimen 14 (33%) 13 (38%)
Conditioning regimen Melphlan 16 (38%) 7 (20%)
IgG 21 (51%) 19 (56%)
IgA 8 (20%) 9 (26%)
IgM 4 (9%)
Mortality 13 (31%) 21 (62%)
Overall survival 65% 25%
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analysis. There were a signiﬁcant interaction between regi-
mens and disease (HL and NHL). For patients with NHL, there
was no signiﬁcant difference in outcomes with BEAM,
CBVlow, BuCy, and TBI. In contrast, NHL patients treated with
CBVhigh had higher progression (HR 1.28 [1.08, 1.50],
p¼0.003), and mortality (HR 1.27 [1.08, 1.49], p¼0.003). For
patients with HL, BuCy and TBI were associated with higher
progression at 3 years compared to BEAM (47%, 57% vs. 36%)
and shorter overall survival (65%, 47% vs. 79%). Multivariable
results for HL are demonstrated in the table.
Conclusion: The impact of speciﬁc high-dose regimens
with AutoHCT on overall outcomes appears to be different in
patients with NHL and HL. Use of CBVhigh in patients with
NHL and BuCy or TBI-containing regimens in HL were asso-
ciated with worse outcomes compared to BEAM. Future
investigation should be geared towards guiding the choice of
regimen based on speciﬁc patient and disease characteristics.37
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Background: Chromosomal abnormalities detected by
interphase ﬂuorescence in situ hybridization (I-FISH) are
an important prognostic marker in patients with multiple
myeloma (MM). Isolated chromosome 13q has been
considered standard risk when identiﬁed by I-FISH and high
risk by conventional cytogenetics. The impact of additional
cytogenetic abnormalities with chromosome 13q identiﬁed
by I-FISH in regards to prognosis has not been fully deﬁned.
In this report, we describe the outcome of patient’s with
multiple myeloma with isolated chromosome 13q and 13q+
(additional cytogenetic abnormalities) identiﬁed by I-FISH at
our institution between January 2003 and January 2013 and
had I-FISH analysis prior to treatment.
Methods: The primary objective was to compare patient’s
outcomes in regards to response, time to progression, and
overall survival between patients who had an isolated 13q
and 13q+ identiﬁed by I-FISH in the bone marrow plasma
cells. Kaplan & Meier curves were generated to calculate
overall survival (OS) between the two groups.
Results: Between January 2003 and January 2013, we iden-
tiﬁed 76 patients by I-FISH who had either an isolated 13q or
13q+ in patients with multiple myeloma (Patient chara-
cteristics Table 1). Of the patients with an isolated 13q
abnormality 33% received a bortezomib-based regimen and
38% in the 13q+ group. Of the patient’s with a isolated 13q
38% went onto receive high dose chemotherapy followed
by autologous ASCT while 20% with a 13q+ received ASCT.African American patients with 13q consisted of 65% and
60% with 13q+ in our patient population. For the 13q or
13q+ who underwent high dose chemotherapy followed
by ASCT OS was 85% compared to the non-transplant
group 45% (p¼0.01) (Figure 2). On follow up at a median of
2.5 years mortality occurred in 31% of the 13q patients
compared to 62% in the 13q+ group. The overall survival at
5 years was 25% in the 13q+ group compared to 65% in the
patient’s with an isolated 13q, With the 13q+ group having
an overall poor OS (p¼0.03)
Conclusion: Patients who harbor the 13q and additional
cytogenetic abnormalities identiﬁed by I-FISH have a signif-
icant worse outcome compared to patients with an isolated
13q. These patients should be considered high risk and
consideration for treatment with novel agents and autolo-
gous stem cell transplant followed by post-transplant
maintenance therapy should be considered.
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Background: Hepatitis B core antibody (HBcAb) seroposi-
tivity has been associated with a higher rate of hepatitis
B reactivation after chemotherapy, even in patients who are
hepatitis B surface antigen (HBsAg)-negative. We evaluated
the incidence of hepatitis B reactivation and liver toxicity
in patients with multiple myeloma (MM) who received
high-dose chemotherapy (HDC) and autologous hematopoi-
etic stem cell transplantation (auto-HCT) at our institution.
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B infection (HB infection¼ HBcAb positive, HBsAg negative)
and 138 patients with normal HB serology (control) who
were matched for age, time of auto-HCT, disease status and
preparative regimen. Both groups received HDC + auto-HCT
between 1989 and 2012. Primary endpoints were: 1) HB viral
reactivation: HBsAg positivity or 10-fold increase in HB viral
DNA; 2) hepatotoxicity, as deﬁned in NCI CTCv3.0.
Results: There were no signiﬁcant differences in immuno-
globulin subtype, bone marrow plasmacytosis, serum beta-2
microglobulin, albumin, creatinine or lactic dehydrogenase
(LDH) between the HB infection or the control group.
Approximately 70% in each group received melphalan alone
as preparative regimen. In the HB infection group, 52
patients (48%) were HBsAb-positive, and 23 (21%) had
detectable HB viral DNA prior to auto-HCT. Serum HB viral
DNA level was<100 IU/m in 22 patients, and<300 IU/ml in 1
patient. HB e antigen (HBeAg) was non-reactive in all 4
patients evaluated prior to auto-HCT. Only 1 patient with HB
infection received pre-emptive antiviral therapy with Lam-
ivudine, while 4 patients received Lamivudine (3) or
Tenofovir (1) at reactivation for a median duration of 1 year.
HB viral reactivation was seen in 6 of 108 (5.6%) in the HB
infection group vs. 0 of 138 in the control group (p¼0.006).
There was a >10-fold increase in HB viral DNA in 5 of 6
patients with HB viral reactivation, and in 2 of 5 HBeAg also
became reactive. Median time to HB reactivation from auto-
HCT was 2.6 years. NCI CTCv3.0 grade 1, 2, 3 or 4 increase in
alanine transferase, aspartate transferase, total bilirubin or
alkaline phosphatase was seen in 6, 1, 2 and 3 patients,
respectively in the HB infection group (9.3%) vs. 1, 2, 0 and
1 (2.9%) patients in the control group (p¼ 0.049). Only one
patient (0.9%) in the HB infection group vs. 6 (4.3%) in control
group died of non-relapse causes within 1-year of auto-HCT
(p¼0.13).With a median follow up of 30 and 28months in HB
infection vs. control groups, the median PFS was 21.4 and
18.7 months, respectively (p¼0.66). Median OS in HB
infection and control groups was 57.0 vs. 65.2 months,
respectively (p¼0.93).
Conclusion: Resolved HB infection is associated with a
signiﬁcant risk of HB viral reactivation and hepatotoxicity in
patients undergoing auto-HCT for MM. These complications
were reversible and were not associated with an increase in
TRM, PFS or OS.
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Background: Lenalidomide (LEN) in combination with stan-
dard-dose melphalan has shown signiﬁcant anti-multiplemyeloma (MM) activity. In this phase I/II trial we evaluated
the safety and efﬁcacy of combining escalating doses of LEN
and high-dose melphalan (HDM) for patients undergoing
autologous hematopoietic stem cell transplantation (auto-
HCT) for relapsed MM.
Methods: Doses were chosen adaptively for successive co-
horts of size 3 using an extension of the safety-efﬁcacy trade-
off design.Each cohort received melphalan 200 mg/m2plus
LEN at one of the four dose levels orally, for 7 days. Primary
endpoints were dose-limiting toxicity (DLT), deﬁned as
regimen-related death, graft failure, grade 3 or 4 atrial
ﬁbrillation, grade 4 deep venous thrombosis, or pulmonary
embolism occurring within 30 days post auto-HCT, and
efﬁcacy, deﬁned as complete response (CR) at day +90.
Results: 57 patients were enrolled between March 2010 and
April 2013. After safely escalating to 100 mg of LEN, patients
were adaptively randomized among the 4 LEN dose levels.
Three, 5, 24 and 25 patients were treated at 25, 50, 75 or 100
mg respectively. Median age at auto-HCT was 60 (34-72)
years, and median time from diagnosis to auto-HCT was 33
(5-214) months, with no signiﬁcant differences between the
4 dose levels. Sixteen (28%) patients had high-risk abnor-
malities on conventional cytogenetic or ﬂuorescent in-situ
hybridization (FISH) studies. Median prior lines of treatment
were 3 (1-11). Eighteen patients (32%) had a prior auto-HCT.
Twenty-four (42%) patients received post auto-HCT mainte-
nance. DLT was not seen at any of the 4 dose levels prior to
adaptive randomization. Grade 3-4 non-hematologic toxicity
was seen in 40 (70%) patients, with no signiﬁcant differences
between the 4 dose levels. Two patients died of nonrelapse
causes (viral infection 1, cardiac failure 1) with a TRM of 3%.
Median time to both neutrophil and platelet engraftment
was 11 days. At day 90, 7 (12%) patients achieved a CR, 30
(53%) achieved CR or very good partial response (VGPR), and
51 (89.5%) achieved CR, VGPR or partial response (PR), with
no signiﬁcant differences in response rates among the 4 LEN
dose levels. With a median follow up of 10.5 months (range
0.5-33.4), median progression-free (PFS) and overall survival
(OS) have not yet been reached. One and 2-year PFSwere 63%
and 59%, respectively. One and 2-year OS were 82% and 72%,
respectively. These compare favorably with our previous
experience of 2-year PFS and OS of 24% and 59%, respectively,
after salvage auto-HCT with melphalan alone. No second
primary malignancy (SPM) has been seen so far.
Conclusion: LEN up to 100 mg daily x 7 days can be safely
combined with high-dose melphalan for relapsed myeloma.
The regimen is associated with a high overall response rate
and 2 year PFS and OS of 59% and 72% in relapsed and heavily
pretreated patients, with no SPM so far.
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Treatment of AL amyloidosis with high dose intravenous
melphalan and autologous stem cell transplant (HDM/SCT) is
effective in inducing hematologic and clinical remissions
associated with prolonged survival. We have performed 607
transplants from July 1994 to August 2013 in the Amyloidosis
Center at Boston Medical Center. Patients were enrolled in
several sequential IRBeapproved protocols.
